Zhang Qiyu, Liang Qiongyu, Sun Jiapeng, Xu Chi
Department of Interventional Treatment, Beijing No. 6 Hospital, Beijing, China.
Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Medicine (Baltimore). 2025 Aug 29;104(35):e44090. doi: 10.1097/MD.0000000000044090.
Breast cancer patients have an increased risk of developing second primary malignancies, with lung cancer accounting for approximately 5% of cases. Differentiating between metastatic disease and a second primary malignancy remains a diagnostic challenge.
A 45-year-old woman with a history of triple-negative breast cancer presented with a newly detected chest wall nodule during routine follow-up.
Contrast-enhanced imaging suggested metastatic disease. However, biopsy and immunohistochemistry confirmed a second primary lesion, consistent with either pulmonary sarcomatoid carcinoma or chest wall sarcoma.
The patient underwent a multimodal interventional regimen, including transarterial embolization followed immediately by radiofrequency ablation.
At 1 month post-treatment, follow-up imaging demonstrated significant tumor shrinkage with no evidence of local recurrence.
This case underscores the importance of comprehensive diagnostic evaluation to distinguish metastatic disease from second primary malignancies in breast cancer patients. It also highlights the potential of interventional therapy as a minimally invasive treatment option for inoperable tumors, with multidisciplinary management being essential to optimize outcomes and prognosis.
乳腺癌患者发生第二原发性恶性肿瘤的风险增加,其中肺癌约占病例的5%。区分转移性疾病和第二原发性恶性肿瘤仍然是一项诊断挑战。
一名45岁有三阴性乳腺癌病史的女性在常规随访期间出现新发现的胸壁结节。
增强成像提示转移性疾病。然而,活检和免疫组化证实为第二原发性病变,符合肺肉瘤样癌或胸壁肉瘤。
患者接受了多模式介入治疗方案,包括经动脉栓塞,随后立即进行射频消融。
治疗后1个月,随访成像显示肿瘤明显缩小,无局部复发迹象。
该病例强调了全面诊断评估对于区分乳腺癌患者转移性疾病和第二原发性恶性肿瘤的重要性。它还突出了介入治疗作为不可切除肿瘤的微创治疗选择的潜力,多学科管理对于优化结果和预后至关重要。